Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Secondary glaucoma after congenital cataract surgery

Poster Details

First Author: L.Cilečková CZECH REPUBLIC

Co Author(s):    J. Cendeli­n   D. Barakova   D. Dotelova              

Abstract Details

Purpose:

To evaluate the occurance of secondary glaucoma after congenital cataract surgery provided on up to the age of 4 months. To consider the presence of the persistent fetal vasculature (PFV) as a risk factor for the development of secondary glaucoma.

Setting:

The Ophthalmology clinic of the 2nd Medical Faculty, Charles University in Prague, and the Faculty Hospital Motol

Methods:

A retrospective study evaluating records of paediatric patients that were operated on up to the age of 4 months between 2005 - 2014. The group of 144 eyes was divided into 68 artephakic eyes (with primary implanted intraocular lens) and 76 aphakic eyes. In these patients we observed the incidence of secondary glaucoma, considering the possible risk factor: the occurance of the PFV.

Results:

Secondary glaucoma developed in 26 eyes (38,2%) in group of artephakic eyes and in 39 eyes (51,3%) in the group of aphakic eyes. If the PFV was presented we implanted IOL in 9 eyes ( 13,2%) and 16 eyes (21,1%) remained aphakic. Secondary glaucoma in eyes with primary presence of the PFV was diagnosed in 2 eyes ( 22,2%) in artephakic group and in 3 eyes ( 18,7%) in aphakic group. In the case of the absence PFV secondary glaucoma developed in 24 artephakic eyes (40,7%) and in 36 aphakic eyes ( 60%).

Conclusions:

The development of secondary glaucoma after primary indicated congenital cataract surgery was higher in the group of aphakic eyes than in artephakic eyes. In the case of the presence PFV more eyes remained aphakic. The occurance of secondary glaucoma in eyes with PFV was almost equal in both groups. PFV diagnosis was not noted as a risk factor for the development of secondary glaucoma.

Financial Disclosure:

NONE

Back to Poster listing